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1312Surgical Thresholds for Bicuspid
Aortic Valve Associated AortopathyOBJECTIVES This systematic review seeks to present the outcomes of the natural history of aortopathy asso-
ciated with bicuspid aortic valve (ABAV) and after interventions.
BACKGROUND Aortopathy is common in patients with ABAV, and early intervention has been proposed to
reduce the risk of dissection. In asymptomatic patients, the timing of surgical management is based upon imaging
of aortic size, but the actual threshold is based upon observational data and expert opinion. As evidence of high
risk would justify early intervention, we sought to deﬁne the natural history of this condition and after
interventions.
METHODS We undertook a systemic review of the evidence from observational studies of ABAV published up
to June 2013. The primary outcome was annualized all-cause mortality. Secondary outcomes included acute aortic
events, rates of aneurysm enlargement, and peri-operative complications. A random-effects model was used to
combine outcomes. A meta-regression was undertaken to assess the impact of potential covariates.
RESULTS The 32 eligible papers involved 11,045 patients (9,441 BAV and 1,604 control subjects, age 46  14
years). There were 3 major groups, nonoperated bicuspid aortic valve (BAV) patients (ages from 30 to 40 years),
patients after aortic surgery (generally 40 to 60 years of age) and after isolated valve replacement (>60 years of
age). The respective annualized mortality of nonoperated BAV patients was 0.56% (95% conﬁdence interval [CI]:
0.13 to 0.99), compared with 0.78% (95% CI: 0.20 to 1.36) in patients after aortic surgery and 2.39% (95% CI: 1.61 to
3.16) after isolated valve replacement. The annualized acute event rate in nonoperated BAV patients was 0.29%
(95% CI: 0.23 to 0.35), this risk being no different from that of a tricuspid aortic valve (risk ratio: 0.68, 95% CI: 0.34
to 1.36). In the post-surgical series, 30-day mortality varied from 0% to 2.5%, and the risk of acute events was
0.16% (95% CI: 0.0 to 0.32) in patients after aortic surgery and 0.68% (95% CI: 0.42 to 0.94) after isolated valve
replacement. Aortic dilation was at a rate of 0.16 mm/year over 6 decades in healthy BAV subjects and 1.1 
0.15 mm/year in older aortic valve replacement patients.
CONCLUSIONS The risk associated with ABAV varies according to age and clinical setting. Nonetheless,
despite aortic dilatation, the acute aortic event risk of ABAV appears low in current practice. Decision-making
regarding the timing of intervention needs to be made on the basis of the balance between this low risk and
both the morbidity and mortality of surgery. (J Am Coll Cardiol Img 2013;6:1311–20) ª 2013 by the American
College of Cardiology Foundationicuspid aortic valve (BAV) is the most
common congenital cardiac anomaly, with
a prevalence of 0.5% to 2.0% (1). Aortic
root enlargement is considered to be a
component of the BAV syndrome, with a 40%
long-term risk of attaining a diameter >40 mm
(2). Aortic root enlargement is a risk factor for
the occurrence of aortic dissection, and because
the outcomes of acute dissection are still poor,
much emphasis has been placed on preventive
surgery to reduce this risk. However, the problem
with our current, largely pragmatic approach (3),
is that aortic root size has become the main
determinant of the timing of intervention, whenthe physics of aortic root enlargement would
suggest that blood pressure, aortic geometry, and
aortic thickness are also determinants of wall
stress and that the likelihood of rupturing a
stressed aorta is related also to the nature of the
constituent tissue.
Over the last decade, 2 inﬂuential studies have
swung practice and guidelines toward aggressive
surgical management of AA with BAV (4,5).
Nonetheless, studies of aortic events in longitudinal
outcome studies of BAV (6–8) and studies of
outcome after isolated aortic valve replacement
(AVR) (9–11) have suggested a more benign course
than that anticipated from analogy with Marfan
A B B R E V I A T I O N S
A N D A C R O N YM S
AA = ascending aorta
ARS = aortic root surgery
AS = aortic stenosis
AV = aortic valve
AVR = aortic valve replacement
BAV = bicuspid aortic valve
CI = conﬁdence interval
TAV = tricuspid aortic valve
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1313syndrome. Indeed, the rationale of this uniformly
aggressive policy has been questioned (12). The aim
of this systematic review is to put the results in
perspective and analyze the various guidelines (13–
15) and the controversies that they have generated
(16,17).
METHODS
Search strategy. An electronic search was un-
dertaken to identify all articles published up to
June 2013 with “bicuspid aortic valve,” “bicuspid
aortopathy,” “BAV aortopathy,” “ascending
aortic dilatation,” “ascending aortic aneurysm,”
“BAV associations,” and “aortopathy” as
exploded Medical Subject Headings terms.
Publications were retrieved via electronic search
engines (Medline, Scopus, Google Scholar,
Ovid, and the Cochrane Library). In addition,
the reference lists from all retrieved articles and
textbooks were examined for further eligible
studies (Fig. 1).
Deﬁnitions. Standard deﬁnitions for BAV applied
(1), but deﬁnitions for aortic dilation and aneurysm
changed with time, location, and patient age groups,
and these were separately noted.
Study selection. English language studies doc-
umenting follow-up were selected, either for
native or treated BAV, including assessment of
aortic dimensions over time. Exclusion criteria
were articles in languages other than English, case
reports, series of <10 patients or studies with poor
outcome reporting with failure to deﬁne time
period over which the events happened or omit-
ting important observational endpoints. When
multiple publications on the same patient sample
were identiﬁed or if study populations overlapped,
then only the latest report was included. All
studies were assessed by A.H. and reviewed by
T.M.
Data extraction. Data extracted from studies
included year of publication, population de-
mographic data, follow-up length and completeness,
study designs, documentation of hemodynamic ab-
normality, and phenotypic features of the valve and
aortic root. We gathered data on different surgical
options, including aortic valve replacement (AVR),
aortic root surgery (ARS), as well as their compar-
ison. Outcome data included mortality (early and
late), morbidity, and baseline and follow-up aortic
dimensions.
Statistical analysis. Standard descriptive statistics
were used, with standard software (SPSS, Chicago,
Illinois) and software for meta-analysis and meta-regression (Comprehensive Meta-Analysis, Eagle-
wood, New Jersey). Forest plots were constructed
to show the outcomes in various groups. Pooled
hazard ratios and 95% conﬁdence intervals (CIs)
were computed; due to the diverse nature of pop-
ulations and adjustment factors, a random effects
method was chosen for all pooled analyses (18).
Cochrane’s Q test was used to assess heterogeneity
between the studies, and the I2 statistic (which
describes the percentage of variation across studies
that is due to heterogeneity rather than chance) was
reported. We used meta-regression to better un-
derstand causes for heterogeneity (19). Begg’s
funnel plot, Egger’s test (20), and Duval and
Tweedie’s trim and ﬁll (21) were used to examine
publication bias.
RESULTS
Patient characteristics. The selection process is
summarized in Figure 1, and characteristics of
observational and surgical groups are
summarized in Table 1. In total, there
were 11,045 patients, of whom 9,441 had
BAV, with a median age of 50 years.
Two-thirds were men, and the most
frequent valvular pathology was aortic
stenosis. The average length of follow-up
was 7.7 years, with most having 90%
follow-up. With the exception of 4 pro-
spective studies (4,22–24) and 1 registry
(25), the studies were generally retro-
spective observational studies.
The population-based longitudinal studies (6–8)
mainly involved persons in the 4th decade of life,
with aortic stenosis in approximately 20% and
regurgitation in approximately 40%. In contrast,
studies of patients undergoing ARS or AVR for
aortic regurgitation generally involved patients in
the 5th decade (26–28), and patients undergoing
AVR for AS were usually in the 6th decade of life
(4,5,9,10,29,30). Likewise, the size criterion for
intervention is not only heterogeneous but incom-
plete. Tzemos et al. (7) used a trans-sinus diameter
of 35 mm, but most other authors reporting post-
operative data from the last decade have used 45
mm. Previous studies have used 5 cm as the crite-
rion for intervention.
Outcomes. Four studies have examined longitudinal
outcomes of unoperated BAV in the general pop-
ulation and in patients with dilated aortas
(6,7,23,31); the mean mortality was 0.56  0.22%/
year (Fig. 2). Although the long-term survival was
the same as in the general population, the risk of
Figure 1. Search and Selection Process
This ﬂow chart shows the initial search results and ﬁnal review of 32 studies
after consideration of exclusions.
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1314acute aortic events (need for subsequent proximal
aortic surgery or aortic dissection/rupture or sudden
death not attributable to any other cause) was
0.29  0.03/year (Fig. 3). The risk, relative to a
tricuspid aortic valve (TAV) was 0.68 (95% CI: 0.34
to 1.36) (4,11,23,31), although the risk of dissection
or rupture or sudden death in the BAV group is
reported to be 8 to 9 times higher than the general
population (6,7). In most of these studies
(10,11,32), a slightly higher mortality is identiﬁed in
the control subjects, because they are older, with
Russo et al. (4) being the only study to show lower
annualized long-term mortality in the control group.
Goland et al. (9) has shown reduced mortality in the
moderately dilated aorta group as compared with the
normal aorta group, due to a lower prevalence of
coronary artery disease in the former.
In the post-surgery series, the 30-day mortality
was between 0% and 2.5%, similar for most studies.
The long-term outcomes of patients undergoing
AVR were evaluated in 13 studies (Fig. 2). The
annualized mortality was 2.4  0.4%, but these
ﬁndings were heterogeneous (I2 ¼ 99, p < 0.0001).
The acute event rate was 0.68  0.13%/year.Outcomes after ARS were assessed in 5 studies;
the annualized mortality was 0.78  0.30%, with an
annualized event rate of 0.16  0.08%. There was
no signiﬁcant difference between early results for
AVR versus ARS except for slightly higher rates of
bleeding and re-exploration in the combined AVR
and root repair groups (24,33–35).
In all of these categories, the ﬁndings were het-
erogeneous (I2 ¼ 99, p < 0.0001). Figure 4 sum-
marizes the publication bias of studies comparing
outcomes of BAV and TAV. Analysis of outcomes
of BAV conﬁrmed publication bias, evidenced by
Egger’s regression intercept of 46 (95% CI: 30 to
63; p < 0.0001); one-half of the studies would have
needed to be trimmed to overcome bias with the
Duval and Tweedie method.
Aortic dimension increase rate. A study of normal
aortic diameters in a healthy population showed a
uniform rate of 0.16 mm/year over 6 decades (36).
Figure 5 illustrates the dimension increase rate of
the aorta in the setting of BAV at different ages,
emphasizing the accelerating rate of aortic dimen-
sion increase as age progresses (6,7,23,25,31,37,38).
The average rate in the literature is 1.1  0.15
mm/year, with heterogeneity that likely relates
to ethnicity and age. For example, Yasuda (39)
showed much slower aortic dimension increase
ratesdpossibly related to ethnicity. A much slower
rate was reported in TAV in the 7th decade of life,
perhaps involving a group with increased aortic
stiffness. Studies in pediatric populations (22) and
young adults (40) showed a much higher rate of
aortic dimension increase.DISCUSS ION
The ﬁndings of this systematic review of aortop-
athy show that there are a small number of acute
aortic events in community-based populations
with BAV (6,7). Among patients evaluated after
AVR and ARS, mortality and acute events are
rare, although they demonstrate some heteroge-
neity (4,5,9–11). The various studies comparing
results of AVR only versus associated aortic sur-
gery of any form (41,42,43) show that the current
selection of AVR and ARS gives excellent long-
term results. The operative mortality of both
procedures are comparable and low at both expert
centers (43) and an audit of over 50,000 pro-
cedures in the North American database (44). This
favorable outcome is often cited as a justiﬁcation
for early surgery, although morbidity data are less
widely reported.
Table 1. Patient Characteristics of BAV and Control (TAV) Subjects
Author/Year
(Ref. #)
Time
Period
Cutoff
(mm)
Study
Design
Patients Age
Men
(%)
AS
(%)
AR
(%)
ASDAR
(%)
No
AS/AR
F/U
(yrs)
F/U
(%)Total BAV Ctrl BAV Ctr
Abdulkareem 2013 (41) 2002–2009 45 AVR (vs. ARS) 395 192 203 61 67 85 15 0 0 4.6 94
Ahmed 2007 (55) 1997–2004 BAV, serial echo 208 208 0 47 67 59 15 5 21 2
Ali 2010 (10) 1991–2001 50 AVR 215 90 125 63 81 93 1 6 0 7.1 100
Ashikhmina 2010 (26) 1984–2007 AV repair 108 108 41 89 0 100 0 0 5.1 88
Bauer 2002 (56) 1985–1999 ARS (reduction aortoplasty) 115 115 56 65 50 26 18 6 3.3
Beroukhim 2006 (22) 1996–2004 Observational, children 198 101 97 9 8.9 0 0 0 100 5 30
Bogers 2004 (32) 1988–2002 ARS (Ross Procedure) 123 81 42 21 25 56 36 20 44 0 5.5
Boodhwani 2010 (27) 1995–2008 ARS (with reimplantation) 122 122 44 90 0 100 0 0 5 100
Borger 2004 (5) 1979–1993 45 AVR 201 201 56 74 63 22 15 0 10.3 98
Conaglen 2009 (57) 1992–2001 ARS (Ross procedure) 35 35 50 62 40 24 36 0 8.5
Davies 2007 (31) 1985–2005 Observational (aneurysms) 514 70 445 49 64 75 49 41 0 0 8.5
Dayan 2010 (58) 2000–2003 45 AVR 60 60 60 50 83 17 0 0 6.2 97
DeKerchove 2011 (28) 1995–2010 AV repair,  reimplantation 161 161 45 95 0 100 0 0 4 99
Etz 2007 (34) 1987–2005 ARS 206 206 54 84 12 53 26 0 5.9 88
Ferencik 2003 (38) 1991–2000 Observational 68 68 44 81 19 41 40 0 4
Girdauskas 2012 (11) 1995–2000 50 AVR (AS only) 325 153 172 54 75 100 0 0 0 15 100
Goland 2007 (9) 1971–2000 50 AVR 252 252 61 66 50 12 38 0 8.9 99
Hanke 2010 (25) 1991–2002 ARS (Ross procedure) 1,277 906 371 41 23 20 22 58 0 5.7 100
La Canna 2006 (23) 1992–2003 60 Normal BAV, AA > 40 mm 113 27 86 49 61 75 0 0 0 100 3
Mahle 2010 (59) 1990–2009 Observational, children 981 981 0 8.3 70 0 0 0 100 9.5
McKellar 2010 (30) 1960–1995 AVR 1,286 1,286 58 71 77 7 16 0 12 98
McKellar 2011 (8) 1980–1999 Pregnancies, observational 88 88 35 0 12.3
Michelena 2011 (6) 1980–2009 45 Observational population 416 416 35 70 23 59 18 0 20 95
Nazer 2010 (42) 1979–1997 ARS vs. AVR & AA graft 143 143 50 72 40 60 0 0 11.5 99
Oliver 2009 (37) 1989–2008 Observational, coarct 622 622 32 67 7
Ozaslan 2008 (24) 1996–2007 ARS (Ross procedure) 50 50 50 67 28 42 30 0 5 100
Russo 2002 (4) 1975–1985 AVR 100 50 50 51 50 71 42 18 40 0 20
Schafers 2010 (35) 1995–2009 ARS 155 155 51 85 0 72 28 0 4.9 99
Svensson 2011 (43) 1993–2003 AVR only vs. AVRþAA graft 1,810 1,810 55 78 6 96
Tzemos 2008 (7) 1994–2001 35 Observational, population 642 642 35 67 9 96
Wijesinghe 2010 (60) 2006–2010 AVR (percutaneous) 11 11 73 100 0 0 0
Yasuda 2003 (39) 1983–2002 AVR vs. no surgery 45 31 14 51 44 40 60 0 0 9
AA ¼ ascending aorta; AR ¼ aortic regurgitation; ARS ¼ aortic root surgery; AS ¼ aortic stenosis; AV ¼ aortic valve; AVR ¼ aortic valve replacement; BAV ¼ bicuspid aortic valve; Ctr ¼ control;
F/U ¼ follow-up; TAV ¼ tricuspid aortic valve.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 2 , 2 0 1 3 Hardikar and Marwick
D E C E M B E R 2 0 1 3 : 1 3 1 1 – 2 0 Decision Making and Aortopathy
1315Natural history. The natural history of aortopathy of
BAV has been deﬁned in studies of pediatric and
adult populations and observational studies after
AVR, repair, and/or ARS. Epidemiological studies
in healthy young populations (mean age of 35 years)
have shown an acute aortic event rate of 0.031
events/year over 20 years and 0.086 events/year over
9 years (6,7). These longitudinal studies show that
the survival of BAV is comparable to that of the
general population.In contrast, the post-surgical series show a
higher frequency of aortic events and mortality. A
variety of differences between these groups might
account for this, including the age of this patient
group and the performance of surgery for valvular
disease. It has been proposed that the presence
of signiﬁcant AV disease or a particular degree of
dilation, on a background of genetic aortopathy,
initiates a vicious cycle of hemodynamic forces
that potentiates the risk of acute aortic events.
Figure 2. Annualized Mortality of Patients With BAV
Studies are divided into those involving nonoperated patients, bicuspid aortic valve (BAV) patients undergoing aortic valve replacement (AVR),
and those undergoing aortic root surgery. CI ¼ conﬁdence interval.
Figure 3. Annualized Aortic Event Rate of Patients With BAV
Studies are divided into those involving nonoperated patients, BAV patients undergoing AVR, and those undergoing ARS. Abbreviations as in
Figure 2.
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Figure 4. Funnel Plot Analysis for Publication Bias
This plot charts standard error relative to log rate ratio between bicuspid aortic valve (BAV)
and control (tricuspid aortic valve) patients.
Figure 5. Aortic Root Dilation Rate
The rate of aortic root enlargement seems to increase in parallel with the age range of
patients in different studies. BAV ¼ bicuspid aortic valve.
Figure 6. Schematic Illustration of the Correlates of AR Dilation
These correlates are categorized as contributors to increasing diameter and pressure and
weakening of the aortic wall. AR ¼ aortic root; AS ¼ aortic stenosis; BSA ¼ body surface
area.
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1317The landmark paper by Borger et al. (5) showed
the need for re-intervention when AVR alone
was performed in the setting of a moderately
dilated aorta, and from this observation, an aortic
diameter of 45 mm has been adopted as a bench-
mark. However, although patients with moder-
ately dilated aortas have a slightly higher
annualized acute aortic event rate (1.8% vs.
1.64%), they have a more favorable 10-year sur-
vival, reﬂecting a lower prevalence of coronary
artery disease (9). Subsequent work has shown
that this aortopathy represents a group of possibly
separate disease processes and a patient phenotype
tailored approach achieves the best results
(11,29,45).
Surgical threshold. Currently, aortic root surgery is
not usually performed if the root measurement is
<4.5 cm, or ratio of maximal AA area (in cm2)/
height in meters is <10 (13). Nonetheless, some
authors have recommended AA surgery at 40 mm
along with concomitant AVR, if operative risk is
low and expected survival is 1 decade or longer (46).
The IRAD registry (International Registry of
Aortic Dissection) has shown that BAV accounted
for 64 of 1,629 (3.9%) dissections from 1996 to
2011, which is 2 or 3 times the prevalence of BAV
in the general population (47). However, the rate of
dissection in aortas <5 cm was the lowest in BAV
patients, as compared with Marfan syndrome or
TAV. Of patients suffering aortic dissection, one-
third have a normal or minimally enlarged aorta,
and only 10% had aortic aneurysms (deﬁned as
$50% increment of aortic size) (48). However, only
0.2% of events occur at an aortic diameter
of <45 mm (43), and the application of this
threshold in 395 patients led to the recognition of
no aortic dilation over 4.6 years of follow-up (41).
Many recent studies propose 4.5 cm as the appro-
priate cutoff (43), but it is quite possible that a
5.0-cm cutoff would not have resulted in a different
long-term picture. Perhaps the ideal cutoff point
should be decided by a composite index incorpo-
rating the thickness, geometry, and tissue charac-
teristics along with diameter and blood pressure
rather than an absolute diameter value.
Figure 6 summarizes the factors affecting aortic
dilation and acute aortic events. Although a
comparison between genetic or hemodynamic
theories of aortic dissection is beyond the scope
of this paper, no histological differences were
identiﬁed by Robicsek et al. (49) in a comparison
of fetal BAV and control aortic tissue. It seems
likely that a genetic predilection is compounded by
hemodynamic and shear-stress insults to produce
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1318aortopathy. Current guidelines for aortic surgery
(13,14) focus mainly on diameter, with the deﬁ-
nition of normal aortic dimension and the effect
of height, weight, and body surface area on
“normal” values being based on studies with rela-
tively small numbers (36,50). Recent studies of
aortic thickness (51), aortic stiffness (52), shear-
stress patterns, and strain measurements
(40,53,54) suggest that incorporation of these
parameters in a composite index might better
predict the risk of acute aortic events than only
diameter-based indexes.
CONCLUS IONS
Recent population-based studies with long-term
follow-up show that, although there is morbidityassociated with BAV, this has not resulted in
adverse effect on mortality as compared with the
general population. To the extent that this can be
attributed to good surveillance and excellent surgical
support, these ﬁndings support current guidelines.
Given the prevalence of BAV, the universal appli-
cation of screening and surgery represents a costly
endeavor from a public health standpoint. In the
absence of a randomized trial, additional evidence
from statistical modeling might be of value to
conﬁrm the value of the current guidelines on a
population-wide basis.
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